XTX Topco Ltd Acquires 10,770 Shares of Vaxcyte, Inc. (NASDAQ:PCVX)

XTX Topco Ltd boosted its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 355.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,796 shares of the company's stock after buying an additional 10,770 shares during the quarter. XTX Topco Ltd's holdings in Vaxcyte were worth $521,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of the stock. Bridgefront Capital LLC boosted its stake in Vaxcyte by 4.2% during the fourth quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock worth $347,000 after buying an additional 172 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Vaxcyte by 10.9% in the first quarter. Nisa Investment Advisors LLC now owns 2,977 shares of the company's stock valued at $112,000 after purchasing an additional 293 shares in the last quarter. Avior Wealth Management LLC grew its holdings in shares of Vaxcyte by 5.3% in the first quarter. Avior Wealth Management LLC now owns 6,799 shares of the company's stock valued at $257,000 after purchasing an additional 343 shares in the last quarter. Xponance Inc. grew its holdings in shares of Vaxcyte by 4.7% in the first quarter. Xponance Inc. now owns 9,320 shares of the company's stock valued at $352,000 after purchasing an additional 415 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Vaxcyte by 1.5% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,635 shares of the company's stock valued at $1,119,000 after purchasing an additional 436 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on PCVX. Cowen reiterated a "buy" rating on shares of Vaxcyte in a report on Thursday. Cantor Fitzgerald began coverage on shares of Vaxcyte in a report on Tuesday, April 22nd. They issued an "overweight" rating for the company. Ten analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $136.50.

Vaxcyte Stock Performance

Shares of NASDAQ PCVX traded down $0.11 during trading hours on Friday, hitting $29.90. The stock had a trading volume of 1,956,003 shares, compared to its average volume of 1,189,025. The company has a market capitalization of $3.88 billion, a P/E ratio of -7.27 and a beta of 1.21. The firm's 50-day moving average price is $34.43 and its two-hundred day moving average price is $48.42. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings results on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter last year, the company earned ($1.10) earnings per share. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.